L. De Prado Gomez, I. Pavord, W. Busse, C. Brightling, M. Wechsler, K. Rabe, M. Zhang, J. Xing, J. Jacob-Nara, P. J ROWE
{"title":"随机、双盲、安慰剂对照研究评估dupilumab预防未控制的中重度哮喘患者肺功能下降(LFD)的长期效果:ATLAS试验","authors":"L. De Prado Gomez, I. Pavord, W. Busse, C. Brightling, M. Wechsler, K. Rabe, M. Zhang, J. Xing, J. Jacob-Nara, P. J ROWE","doi":"10.1183/13993003.congress-2022.2288","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":414532,"journal":{"name":"05.02 - Monitoring airway disease","volume":"32 5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Randomised, double-blind, placebo-controlled study to assess long-term effect of dupilumab on prevention of lung function decline (LFD) in patients with uncontrolled moderate-to-severe asthma: ATLAS trial\",\"authors\":\"L. De Prado Gomez, I. Pavord, W. Busse, C. Brightling, M. Wechsler, K. Rabe, M. Zhang, J. Xing, J. Jacob-Nara, P. J ROWE\",\"doi\":\"10.1183/13993003.congress-2022.2288\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":414532,\"journal\":{\"name\":\"05.02 - Monitoring airway disease\",\"volume\":\"32 5 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"05.02 - Monitoring airway disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1183/13993003.congress-2022.2288\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"05.02 - Monitoring airway disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.congress-2022.2288","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Randomised, double-blind, placebo-controlled study to assess long-term effect of dupilumab on prevention of lung function decline (LFD) in patients with uncontrolled moderate-to-severe asthma: ATLAS trial